Obesity

GLP-1 therapies have redefined what obesity pharmacotherapy can achieve, but efficacy is no longer the only battleground.

What Patients Need Next and Who Will Deliver It

Reflections on SGO 2026

New global syndicated survey highlights a striking contradiction at the heart of how obesity is understood, especially by those living with it.

New 14-country study from Ipsos reveals self-blame, outdated narratives and a hidden daily toll.

Despite media discussions around the drugs, only around a third across 30 countries have heard about the drugs, with a lot of the discourse taking place via social media according to the Ipsos Health Service Report.

Ipsos’ latest AI-powered innovation offers unparalleled insights into the fast-moving consumer obesity treatment market – while reinforcing Ipsos’ position at the forefront of AI applications in market research.

Our evolutionary tale began 6 million years ago, when humans were programmed to hoard calories in a world of scarcity. Today, that ancient wiring has become our greatest health risk.

Security, Inflation, Perils of Perception … Ipsos Update explores the latest and research & thinking on key topics from Ipsos teams around the world.